Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.81B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 1.02M
Average 0.71M
ZYME Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Zymeworks Inc.NASDAQ: ZYME
Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026
Cash & equivalents rises 55.0% from a year ago
Cash & equivalents stood at $100.46M at the end of Q3 FY2026, up 55.0% from a year earlier and down 44.0% from the prior quarter. Over 3 fiscal years it compounded at -53.2% a year.
Context
- Cash & equivalents amounted to 8.5% of total assets at the end of Q3 FY2026, down 7.8 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +55.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 41.16M USD
- Year-over-year change
- -37.7%
- 4-year CAGR
- -32.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.16M | -37.7% |
| FY2024 | 2024-12-31 | 66.1M | -58.0% |
| FY2023 | 2023-12-31 | 157.56M | -60.7% |
| FY2022 | 2022-12-31 | 400.91M | +98.6% |
| FY2021 | 2021-12-31 | 201.87M | — |
Cash & Equivalents vs competitors
How ZYME compares with its peers on the latest reported figures
- ZYME's Sep 2026 cash & equivalents of $100.46M is the 5th highest of the 11 companies compared; the peer median is $55.59M.
- Its year-over-year change of +55.0% is the 4th highest of 11, against a peer median of -7.1%.
- Cash & equivalents amounts to 8.5% of total assets for ZYME, versus a peer median of 24.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Aug 2026 | $720.24M | +818.2% | +56.5% | 60.3% | |
| Mar 2026 | $231.01M | +18.6% | -7.1% | 79.2% | |
| Sep 2026 | $212.84M | -21.9% | +218.0% | 42.1% | |
| Mar 2026 | $189.16M | +3269.4% | +64.5% | 95.0% | |
| Sep 2026 | $100.46M | +55.0% | -53.2% | 8.5% | |
| Mar 2026 | $66.52M | -54.3% | -19.3% | 30.5% | |
| Jun 2026 | $44.66M | +0.5% | +0.1% | 6.2% | |
| Mar 2026 | $32.28M | +56.6% | -30.5% | 18.1% | |
| Mar 2026 | $28.83M | -39.4% | -59.7% | 8.0% | |
| Sep 2026 | $26.95M | -25.2% | -0.6% | 3.7% | |
| Mar 2026 | $12.44M | -14.7% | +101.6% | 8.5% | |
| Peer median (excluding ZYME) | $55.59M | -7.1% | -0.3% | 24.3% | |
Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 201.87M | 400.91M | 157.56M | 66.1M | 41.16M |
| Short-term Investments | 50.74M | 91.32M | 216.77M | 159.67M | 187.64M |
| Net Receivables | 15.61M | 33.4M | 19.48M | 55.82M | 4.64M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 19.07M | 19.12M | 18.86M | 0 |
| Total Current Assets | 288.22M | 544.71M | 412.93M | 300.45M | 233.44M |
| Property, Plant & Equipment (Net) | 49.77M | 47.65M | 37.54M | 34.32M | 0 |
| Goodwill | 12.02M | 12.02M | 12.02M | 12.02M | 12.02B |
| Intangible Assets | 21.47M | 26.38M | 25.28M | 4.58M | 1.35B |
| Long-term Investments | 886K | 886K | 81.93M | 98.43M | 41.79M |
| Tax Assets | 3.07M | 1.35M | 3.62M | 4.39M | 0 |
| Other Non-current Assets | 13.7M | 15.74M | 7.57M | 8.92M | (13.29B) |
| Total Non-current Assets | 100.91M | 104.02M | 167.95M | 162.64M | 113.09M |
| Total Assets | 389.13M | 648.73M | 580.88M | 463.09M | 346.53M |
| Account Payables | 5.17M | 7.86M | 6.21M | 3.9M | 4.4M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 17.08M | 1.81M | 1.38M | 0 |
| Deferred Revenue | 0 | 2.35M | 3.7M | 25.59M | 2.42M |
| Other Current Liabilities | 11.1M | 16.01M | 8.68M | 7.49M | 9.67M |
| Total Current Liabilities | 71.85M | 95.63M | 55.76M | 88.29M | 42.32M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 1.57M | 1.79M | 3.3M | 4.76M | 6.03M |
| Deferred Revenue (Non-current) | 32.94M | 30.59M | 32.94M | 14.61M | 14.61M |
| Other Non-current Liabilities | 2.65M | 2.98M | 1.61M | 895K | 278K |
| Total Non-current Liabilities | 68.19M | 60.14M | 60.31M | 36.03M | 35.71M |
| Total Liabilities | 140.04M | 155.77M | 116.07M | 124.32M | 78.03M |
| Common Stock | 741.15M | 906.76M | 1.01B | 1.02B | 1.11B |
| Retained Earnings | (683.1M) | (558.76M) | (677.44M) | (830.34M) | (953.16M) |
| Accumulated OCI | (6.66M) | (6.66M) | (6.6M) | (6.95M) | (6.08M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 249.09M | 492.96M | 464.81M | 338.77M | 268.5M |
| Total Debt | 32.33M | 28.11M | 26.72M | 18.51M | 18.27M |
| Net Debt | (169.53M) | (372.8M) | (130.84M) | (47.6M) | (22.89M) |
Zymeworks Inc.
NASDAQ:ZYME
Intrinsic Alpha fair value
Locked
Current Price
$26.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.